Response-based chemotherapy and involved field radiation for intermediate stage Hodgkin disease. A GISL/NHLSG trial

被引：0
|
作者：
Iannitto, E. [1 ]
Minardi, V. [1 ]
Gobbi, P. G. [2 ]
Luminari, S. [3 ]
Calvaruso, G. [1 ]
Stelitano, C. [4 ]
Baldini, L. [5 ]
Merli [6 ]
Petrini, M. [7 ]
Marcheselli, L. [3 ]
Mammi, C. [3 ]
De Cantis, S. [1 ]
Abbadessa, V [1 ]
Federico, M. [3 ]
机构：
[1] Univ Palermo, I-90133 Palermo, Italy
[2] Univ Pavia, I-27100 Pavia, Italy
[3] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy
[4] Osped Bianchi Melacrino Morelli, Reggio Di Calabria, Italy
[5] Univ Milan, Dipartimento Ematol, I-20122 Milan, Italy
[6] Osped SM Nuova, Reggio Emilia, Italy
[7] Univ Pisa, I-56100 Pisa, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 1
页数：1
相关论文
共 50 条
  • [41] Fifteen year experience of A(E)BVD chemotherapy plus low dose involved field radiation therapy for early clinical stage Hodgkin's lymphoma (HL). Does radiation dose affect patients' outcome?
    Vassilakopoulos, TP
    Angelopoulou, MK
    Siakantaris, MP
    Kyrtsonis, MC
    Kontopidou, FN
    Dimopoulou, MN
    Kokoris, SI
    Dimitriadou, E
    Tsaftaridis, P
    Variamis, E
    Zambatis, H
    Michalopoulos, E
    Boussiotis, VA
    Panagiotidis, P
    Papavassileiou, K
    Pangalis, GA
    BLOOD, 2003, 102 (11) : 405A - 405A
  • [42] Impact of involved field radiotherapy after chop-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas
    Schlembach, PJ
    Wilder, RB
    Tucker, SL
    Ha, CS
    Rodriguez, MA
    Hess, MA
    Cabanillas, FF
    Cox, JD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (04): : 1107 - 1110
  • [43] Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD plus radiation therapy for early stage non bulky Hodgkin's disease.
    Straus, DJ
    Yahalom, J
    Zelenetz, AD
    Qin, J
    Myers, J
    Moskowitz, CH
    Noy, A
    Bertino, JR
    Portlock, CS
    BLOOD, 2001, 98 (11) : 769A - 769A
  • [44] Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients (pts) with intermediate-stage Hodgkin's disease (HD): A randomized multicenter study.
    Engert, A
    Schiller, P
    Pfistner, B
    Herrmann, R
    Koch, P
    Bossevin, F
    Schaber, R
    Loeffler, M
    Duehmke, F
    Mueller-Hermelink, HK
    Paulus, U
    Rueffer, JU
    Sieber, M
    Wolf, J
    Diehl, V
    BLOOD, 2001, 98 (11) : 768A - 768A
  • [45] Phase I study of involved field radiation therapy preceding high dose chemotherapy and autologous stem cell transplantation in patients with high risk Hodgkin's disease and non-Hodgkin's lymphoma.
    Saito, NG
    Dawson, LA
    Eisbruch, A
    Ratanatharathorn, V
    Uberti, JP
    Adams, PT
    Silver, SM
    Ayash, LJ
    Reynolds, CM
    Schipper, MJ
    Lichter, AS
    BLOOD, 2002, 100 (11) : 864A - 864A
  • [46] Minimal initial chemotherapy plus involved field radiotherapy (RT) versus mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial.
    Radford, J
    Williams, MV
    Hancock, BW
    Hoskin, P
    Sun-Mynt, H
    Smith, P
    Qian, W
    Linch, D
    BRITISH JOURNAL OF CANCER, 2004, 91 : S1 - S1
  • [47] Final results of a randomized trial (HD 4): 30 Gy extended field plus 10 Gy involved field radiation is equally effective to 40 Gy extended field radiation in patients with Hodgkin's disease PS I/II.
    Ruffer, U
    Sieber, M
    Tesch, H
    Paulus, U
    Koch, T
    Pfreundschuh, M
    Georgii, A
    Staar, S
    Duhmke, E
    Diehl, V
    BLOOD, 1997, 90 (10) : 2604 - 2604
  • [48] 12 weeks of chemotherapy (stanford V) and involved field radiotherapy (RT) are highly effective for bulky and advanced stage Hodgkin's disease (HD): A limited institution ecog pilot study.
    Horning, SJ
    Bennett, JM
    Bartlett, NL
    Williams, J
    Neuberg, D
    Cassileth, PA
    BLOOD, 1996, 88 (10) : 2681 - 2681
  • [49] Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
    Rosenbrock, Johannes
    Kaul, Helen
    Oertel, Michael
    Celik, Eren
    Linde, Philipp
    Fan, Jiaqi
    Eichenauer, Dennis A.
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Kobe, Carsten
    Dietlein, Markus
    Fuchs, Michael
    Borchmann, Peter
    Eich, Hans Theodor
    Baues, Christian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (05): : 1344 - 1352
  • [50] Four cycles of ABVD followed by involved field irradiation (IF-RT) is the treatment of choice for early-stage Hodgkin's disease (HD): 5-year results of a randomized trial
    Santoro, A
    Bonfante, V
    Viviani, S
    Zanini, M
    Devizzi, L
    Parra, HS
    DiRusso, A
    Soncini, F
    Villani, F
    Valagussa, P
    Bonadonna, G
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1185 - 1185
12345